Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd > A Great New Add to the Executive Team
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(81)
•••
Post by biggdoggon Sep 17, 2024 2:23pm
118 Views
Post# 36227626

A Great New Add to the Executive Team

A Great New Add to the Executive TeamThe criticism from those lacking education is often surprisingly quick. The Chief Science Officer's previous tenure at a pharmaceutical company, despite unsuccessful drug trials, should not be viewed negatively. It's all about the wealth of experience she brings. A brief internet search reveals much more and reveals that she is a remarkable hire. Sounds Like voyageur has the talent to advance with the FDA and their drug development, Impressive. This has been a position to be filled for a long time, it will bring credibility to the management team in the eyes of the pharma investment community.

Peer reviewed
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1317522/full
https://www.nature.com/articles/s42003-023-05536-0
https://www.frontiersin.org/journals/natural-products/articles/10.3389/fntpr.2023.1281061/full
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1119607/full
https://pubmed.ncbi.nlm.nih.gov/36923728/
https://www.nature.com/articles/s41598-021-91500-z
https://www.nature.com/articles/s41598-018-20608-6
https://www.nature.com/articles/srep30555
Patents
https://ipsearch.ipaustralia.gov.au/patents/2016228147
https://patents.google.com/patent/EP3265114A1/en

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities